Islamabad, Sep 20: Citi Pharma Limited (PSX: CPHL), Pakistan’s largest API manufacturer, has made history by becoming the first company in the country to receive FDA approval for its nutraceutical products in the United States, with a formal launch scheduled for September 2024.
Approved Categories
Citi Pharma received FDA approvals in the following areas:
- Fertility
- Weight Management
- Stress and Mood Booster
- Hair & Skin Care
- Joint and Muscle Pains
This approval enables the company to enter the competitive US market, allowing it to export finished nutraceutical products.
Product Line
Citi Pharma offers a diverse range of products, including:
- Tablets
- Capsules
- Powder Sachets
- Syrups
- Ointments and Gels
- Injections
- Infusions and Suspensions
Financial Outlook
The company anticipates generating approximately $3 million annually from this new revenue stream, with profit margins expected to be between 25-30%.
“This FDA approval not only enhances Citi Pharma’s credibility but also positions it as a growing global player, potentially attracting further investment and international partnerships,” the stock filing stated.
At the time of reporting, Citi Pharma’s stock was priced at Rs. 35.72, up 3.63% or Rs. 1.25, with over 2.33 million shares traded on Friday.
